Results Study population characteristics A total of 417,322 patients with AKI who required dialysis were discharged from the hospital
S3 show the results for the outcome MACE: both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk for MACE (13% and 11%, respectively) as compared with placebo, and a lower risk for MACE as compared with DPP-4 inhibitors (12% and 11%, respectively)
One study looked at adults with a new diagnosis of type 2 diabetes
Tirzepatide is a research compound sold for laboratory and research use only
What to Expect: GLP-1 Side Effect Reality Check Nausea : The most frequently reported side effect, typically more prominent when first starting or increasing doses Vomiting : Less common than nausea, possible during initial adjustment Diarrhea or constipation : Can occur alongside other GI effects Reduced appetite : A therapeutic effect that helps with weight loss, but can sometimes feel uncomfortable Many patients report that side effects decrease significantly after the first few weeks, and severe reactions requiring discontinuation are relatively rare
Prescribing GLP-1 agonists for AUD would constitute off-label use , which requires careful consideration of the evidence base, documented informed consent, clear rationale, appropriate monitoring, and adherence to local governance frameworks